Home
  • About Us
    • Inside Absci
    • Team
    • Our Values
  • Our Technology
  • Our Science
    • Posters
    • Manuscripts
    • Case Studies
    • All
  • Pipeline
  • Partner With Us
  • Investors
  • Careers
    • Life at Absci
    • Current Openings
  • Contact Us

Ideas to Impact

Mar 23, 2022

Absci is unlocking the potential of next-generation biologics by merging cutting edge AI models of protein function with experimental biology to explore a vast therapeutic sequence space inaccessible to traditional methods. For more information visit www.absci.com and follow us on social media: Twitter: @abscibio, LinkedIn: @absci.

Related

ABS-101 Case Study: Potential best-in-class TL1A mAb for IBD

ABS-201 Case Study: Potential best-in-class antibody targeting the prolactin receptor for the treatment of androgenic alopecia

IgDesign: In vitro validated antibody design against multiple therapeutic antigens using inverse folding

Share this post


Related Resources


ABS-101 Case Study: Potential best-in-class TL1A mAb for IBD

Read More

ABS-201 Case Study: Potential best-in-class antibody targeting the prolactin receptor for the treatment of androgenic alopecia

Read More

IgDesign: In vitro validated antibody design against multiple therapeutic antigens using inverse folding

Read More
Site
  • About Absci
  • Our Technology
  • Our Science
  • Pipeline
  • Partner With Us
  • Investors
  • Careers
Connect
  • Contact Us
  • LinkedIn
  • X/Twitter
  • YouTube

Unlocking differentiated biology with generative AI

  • Privacy
  • Terms

© Copyright 2025 Absci Corp.

  • Twitter
  • linkedin
  • YouTube
Youโ€™re leaving the Absci website. This link is provided for your convenience, but the content is the sole responsibility of its owner. Do you want to continue?
Return to the Absci website at any time by using the โ€œBackโ€ button on your web browser.
YES
NO